Skip to main content
KyungdongPharm logo

KyungdongPharm — Investor Relations & Filings

Ticker · 011040 ISIN · KR7011040003 KO Manufacturing
Open in API
Filings indexed 303 across all filing types
Latest filing 2021-10-22 Director's Dealing
Country KR South Korea
Listing KO 011040

About KyungdongPharm

https://kdpharma.co.kr

KyungdongPharm is a pharmaceutical company engaged in the development, manufacturing, and distribution of medicines. Since its establishment in 1975, the company has focused on producing a broad portfolio of specialized therapeutic drugs and general pharmaceuticals. Its product lines encompass prescription medicines, with a focus on areas such as liver therapy, and over-the-counter products, including its prominent painkiller brand, 'Geunal-N'. The company also manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates. Utilizing advanced production facilities and proprietary technology, KyungdongPharm is dedicated to developing high-quality medicines supported by clinical research to contribute to public health.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details specific share transactions (disposals) made by a director (Kim Seok-beom) of Kyungdong Pharmaceutical Co., Ltd. This type of filing is a standard regulatory disclosure for insider trading/shareholding changes by company executives, which falls under the 'Director's Dealing' category.
2021-10-22 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the share ownership, changes in shareholding, and special relationships of major shareholders (such as the CEO and related parties) in Kyungdong Pharmaceutical Co., Ltd. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided taxonomy.
2021-09-02 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Correction Report' (정정신고) for a 'Pledge of Shares by the Largest Shareholder' (최대주주 변경을 수반하는 주식 담보제공 계약 체결). This type of disclosure is a standard regulatory requirement for listed companies in Korea to report changes in collateralized shares held by major shareholders. Since it does not fit into specific categories like M&A, Earnings, or Dividends, and is a formal regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2021-08-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. It details the acquisition of shares by an executive (Oh Dong-il) of Kyungdong Pharmaceutical Co., Ltd. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) report, as it documents personal share transactions by a company insider.
2021-08-24 Korean
주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from a Korean company (Kyungdong Pharmaceutical) regarding a decision to acquire its own shares (자기주식 취득 결정). This is a formal regulatory filing detailing a share buyback program, which falls under the category of a company buying back its own shares.
2021-08-17 Korean
반기보고서 (2021.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for KyungDong Pharmaceutical Co., Ltd., covering the period from January 1, 2021, to June 30, 2021. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which fits the definition of an Interim/Quarterly Report (IR). H1 2021
2021-08-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.